Key result
A novel synthesis method was developed for macitentan, an approved endothelin receptor antagonist.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Novel macitentan synthesis warrants no practice change; leaves open scalable production for ERA research.
Macitentan (systematic name N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy] ethoxy]-4-pyrimidinyl]-N'-propylsulfamide, 5, Scheme 1) is an endothelin receptor antagonist (ERA) approved by the...
No takes yet. Share an insight, caveat, or question.
Nami et al. (2017) studied this question. A novel synthesis method was developed for macitentan, an approved endothelin receptor antagonist.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: